Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clindamycin/tretinoin - Stiefel Laboratories

X
Drug Profile

Clindamycin/tretinoin - Stiefel Laboratories

Alternative Names: Clindamycin phosphate/tretinoin gel; CT Gel; Velac; Veltin

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Astellas Pharma BV
  • Developer Stiefel Laboratories
  • Class Antiacnes; Antibacterials; Keratolytics; Lincosamides; Retinoids; Small molecules
  • Mechanism of Action Protein 50S ribosomal subunit inhibitors; Protein synthesis inhibitors; Retinoic acid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Acne vulgaris
  • Registered Acne

Most Recent Events

  • 05 Jul 2019 Chemical structure information added
  • 23 Nov 2015 Clindamycin/tretinoin 1.2%/0.025% gel licensed to Almirall in USA
  • 13 Aug 2013 No development reported - Phase-III for Acne vulgaris (in adolescents, in adults) in USA, Belize and Canada (Topical)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top